Username Password
S&P 500: 2,000.42
Change: +0.02%
pspavento
P&P Score: 93.75 | Points: 8.93 | Accuracy: 57.14 | Average Pick Score: -35.98   Annual Return: N/A  
Open
 
Closed
 
All
 
Commentary
BUY: DENDREON CORPORATION (DNDN) Rating: 2
Start Price: $23.42
Points: -206.19
Created: 05/30/2009
Easy double or even triple.New prostate cancer drug has2-3 billion $ per year sales potential.Also company maybe takeover target for big pharma cos.

1 Comment(s):

Author pspavento     Date 2010-12-27 22:30:25
they will expanding indications for the drug to men who are NOT terminally ill. My target price for DNDN is $ 80=90 by teh end of 2011. Strong buy !!!
Want to comment on this post? Sign up now. It's FREE!
Already registered? Log In.

register
Sponsored Links